W. Umstead John - Jan 3, 2024 Form 4 Insider Report for G1 Therapeutics, Inc. (GTHX)

Role: Chief Financial Officer
Signature: /s / Monica Roberts Thomas, attorney-in-fact
Stock symbol: GTHX
Transactions as of: Jan 3, 2024
Transactions value $: -$2,298
Form type: 4
Date filed: 1/8/2024, 06:04 AM
Previous filing: May 12, 2023
Next filing: Mar 20, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GTHX	Common Stock	Award	$0	+37.3K	+39.73%	$0.00	131K	Jan 3, 2024	Direct	F1, F2, F3
transaction	GTHX	Common Stock	Sale	-$789	-253	-0.19%	$3.12	131K	Jan 3, 2024	Direct	F4, F5, F6
transaction	GTHX	Common Stock	Sale	-$1.18K	-379	-0.29%	$3.12	131K	Jan 3, 2024	Direct	F4, F5, F7
transaction	GTHX	Common Stock	Sale	-$327	-111	-0.09%	$2.94	130K	Jan 4, 2024	Direct	F4, F8, F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GTHX	Stock Options (Right to Buy)	Award	$0	+74.5K		$0.00	74.5K	Jan 3, 2024	Common Stock	74.5K	$2.97	Direct	F10

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2025 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F10	The shares underlying this option vest as to 25% of the shares on January 3, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F2	Each RSU represents a contingent right to receive one share of Issuer common stock.
F3	Represents (i) 2,749 shares of common stock; (ii) 637 RSUs from award granted on January 4, 2021; (iii) 2,500 RSUs from award granted on January 3, 2022; (iv) 3,000 RSUs from award granted on January 3, 2023; (v) 50,000 RSUs from award granted on March 15, 2023; (vi) 35,000 RSUs from award granted on May 10, 2023; and (vii) 37,300 RSUs from award granted on January 3, 2024.
F4	The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
F5	The price represents the weighted average price with a low of $3.08 and a high of $3.16. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6	Represents (i) 2,996 shares of common stock; (ii) 637 RSUs from award granted on January 4, 2021; (iii) 2,000 RSUs from award granted on January 3, 2022; (iv) 3,000 RSUs from award granted on January 3, 2023; (v) 50,000 RSUs from award granted on March 15, 2023; (vi) 35,000 RSUs from award granted on May 10, 2023; and (vii) 37,300 RSUs from award granted on January 3, 2024.
F7	Represents (i) 3,367 shares of common stock; (ii) 637 RSUs from award granted on January 4, 2021; (iii) 2,000 RSUs from award granted on January 3, 2022; (iv) 2,250 RSUs from award granted on January 3, 2023; (v) 50,000 RSUs from award granted on March 15, 2023; (vi) 35,000 RSUs from award granted on May 10, 2023; and (vii) 37,300 RSUs from award granted on January 3, 2024.
F8	The price represents the weighted average price with a low of $2.89 and a high of $3.00. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9	Represents (i) 3,468 shares of common stock; (ii) 425 RSUs from award granted on January 4, 2021; (iii) 2,000 RSUs from award granted on January 3, 2022; (iv) 2,250 RSUs from award granted on January 3, 2023; (v) 50,000 RSUs from award granted on March 15, 2023; (vi) 35,000 RSUs from award granted on May 10, 2023; and (vii) 37,300 RSUs from award granted on January 3, 2024.